Cargando…
Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment
Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional li...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608678/ https://www.ncbi.nlm.nih.gov/pubmed/36297630 http://dx.doi.org/10.3390/pharmaceutics14102195 |
_version_ | 1784818831704719360 |
---|---|
author | Nikolova, Maria P. Kumar, Enamala Manoj Chavali, Murthy S. |
author_facet | Nikolova, Maria P. Kumar, Enamala Manoj Chavali, Murthy S. |
author_sort | Nikolova, Maria P. |
collection | PubMed |
description | Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications. |
format | Online Article Text |
id | pubmed-9608678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96086782022-10-28 Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment Nikolova, Maria P. Kumar, Enamala Manoj Chavali, Murthy S. Pharmaceutics Review Liposomes are well-known nanoparticles with a non-toxic nature and the ability to incorporate both hydrophilic and hydrophobic drugs simultaneously. As modern drug delivery formulations are produced by emerging technologies, numerous advantages of liposomal drug delivery systems over conventional liposomes or free drug treatment of cancer have been reported. Recently, liposome nanocarriers have exhibited high drug loading capacity, drug protection, improved bioavailability, enhanced intercellular delivery, and better therapeutic effect because of resounding success in targeting delivery. The site targeting of smart responsive liposomes, achieved through changes in their physicochemical and morphological properties, allows for the controlled release of active compounds under certain endogenous or exogenous stimuli. In that way, the multifunctional and stimuli-responsive nanocarriers for the drug delivery of cancer therapeutics enhance the efficacy of treatment prevention and fighting over metastases, while limiting the systemic side effects on healthy tissues and organs. Since liposomes constitute promising nanocarriers for site-targeted and controlled anticancer drug release, this review focuses on the recent progress of smart liposome achievements for anticancer drug delivery applications. MDPI 2022-10-15 /pmc/articles/PMC9608678/ /pubmed/36297630 http://dx.doi.org/10.3390/pharmaceutics14102195 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nikolova, Maria P. Kumar, Enamala Manoj Chavali, Murthy S. Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title | Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title_full | Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title_fullStr | Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title_full_unstemmed | Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title_short | Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment |
title_sort | updates on responsive drug delivery based on liposome vehicles for cancer treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608678/ https://www.ncbi.nlm.nih.gov/pubmed/36297630 http://dx.doi.org/10.3390/pharmaceutics14102195 |
work_keys_str_mv | AT nikolovamariap updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment AT kumarenamalamanoj updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment AT chavalimurthys updatesonresponsivedrugdeliverybasedonliposomevehiclesforcancertreatment |